The only problem with that is MSB and FDA (and Teva) have agreed to 2 Phase 3 trials in heart failure to achieve approval.
And only one has been conducted so far. And it failed to meet its primary endpoint.
Apart from that, accelerated approval is an absolute certainty?I think there is a way to go on this!
BTW - I still believe CHF is their best chance!
- Forums
- ASX - By Stock
- MSB
- MSB 2022 - The road to commercialisation
MSB
mesoblast limited
Add to My Watchlist
1.80%
!
$1.70

MSB 2022 - The road to commercialisation, page-883
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.70 |
Change
0.030(1.80%) |
Mkt cap ! $2.172B |
Open | High | Low | Value | Volume |
$1.67 | $1.74 | $1.67 | $6.647M | 3.897M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 44280 | $1.69 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.70 | 26847 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 44280 | 1.690 |
4 | 54367 | 1.680 |
3 | 34371 | 1.675 |
1 | 6718 | 1.670 |
5 | 88100 | 1.660 |
Price($) | Vol. | No. |
---|---|---|
1.700 | 26847 | 2 |
1.705 | 13250 | 2 |
1.715 | 5539 | 1 |
1.720 | 12648 | 3 |
1.725 | 22531 | 3 |
Last trade - 16.10pm 15/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online